Why This Matters
How do clinicians distinguish an aggressive prostate cancer from an indolent one? Men undergoing prostatectomy have highly variable outcomes: some remain cancer-free for decades, while others relapse within years. Today, pathologists grade tumors on morphology alone, missing critical clues hidden in the tumor microenvironment. The real biology driving aggressive disease may live not just in malignant cells, but in the stromal and immune landscape that surrounds them. A new study reveals that spatial omics can decode this landscape and identify patients at highest risk of relapse before clinical symptoms emerge.
Krossa et al. published “Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment” in Nature Communications on November 19, 2025. The work integrates spatial transcriptomics, bulk RNA-seq, and metabolomics data from human prostate tissue, connected to long-term clinical outcomes from a well-phenotyped cohort. The result is a blueprint for how the immune and metabolic microenvironment encodes cancer aggression.
What They Found
The researchers analyzed tissue from two groups: patients with aggressive prostate cancer who relapsed within a few years of surgery, and patients who remained cancer-free for over a decade. Using high-resolution spatial transcriptomics, they mapped gene expression at the tissue level while preserving location information. They also quantified metabolites in the same samples, asking: what is different in the tumor microenvironment of men destined to relapse?
Two key signatures emerged. Both were enriched in patients with aggressive disease and associated with specific cell types: club-like cells (a luminal-like epithelial population) and immune cell activation. The spatial data revealed that these signatures were not confined to morphologically abnormal tissue. Instead, they showed up in morphologically benign-appearing glands within the tumor microenvironment, highlighting a critical insight: tumors rewire the microenvironment far beyond their visible borders.
The pro-inflammatory chemokine signature revealed elevated immune activity at the tumor-immune interface in aggressive cancers, suggesting active recruitment of immune cells. Metabolomically, aggressive tumors showed characteristic alterations in amino acid and lipid metabolism that were spatially localized to specific microenvironmental regions. These metabolic shifts correlated with immune activation and poor long-term outcomes.
Why This Matters Mechanistically and Clinically
This study tackles a core challenge in cancer medicine: the gap between morphology and biology. Traditional Gleason grading relies on epithelial morphology. But the microenvironment is a living ecosystem that actively shapes cancer evolution. Spatial omics bridges this gap by revealing biochemical and cellular landscapes that predict clinical outcomes.
The finding that metabolic and immune shifts occur in morphologically normal-looking glands is particularly striking. It suggests that “field effects” in the tumor microenvironment encode aggression signals. Clinically, this opens a path to better risk stratification: instead of relying on morphology alone, pathologists could apply spatial omics to prostatectomy specimens to identify men who need intensive surveillance or adjuvant therapy.
The mechanistic insight about club-like cell enrichment and immune activation also hints at targetable biology. Pro-inflammatory chemokines drive immune cell recruitment. Rewiring that communication might block the metastatic niche. Metabolic shifts suggest metabolic dependencies that could be exploited therapeutically.
How They Did It
The team collected prostate tissue from a clinical cohort with long-term follow-up (over 10 years post-prostatectomy). They applied Visium spatial transcriptomics to map thousands of genes across tissue sections while preserving spatial coordinates. They also measured metabolites via mass spectrometry in the same tissue, creating a spatially resolved metabolomics layer. Bulk RNA-seq provided additional depth on transcriptional changes. Data integration identified gene expression and metabolic signatures associated with relapse-free survival, which were validated in independent datasets.
Limitations
Several important caveats constrain the interpretation:
First, this is a retrospective analysis from a single institution. While the follow-up is long (10 years), the sample size and potential selection bias need consideration. Prospective validation in independent cohorts is essential.
Second, spatial omics is correlative. The signatures identify associations between microenvironmental features and aggression, but do not prove causation. It remains unclear whether rewired metabolism and immune activity cause aggressive disease or are consequences of it.
Third, the study focuses on the primary tumor microenvironment. Metastatic progression involves colonization of distant sites, which has distinct selective pressures and stromal interactions. The degree to which these microenvironmental signatures predict metastatic competence across different organs is unknown.
Fourth, prostate cancer is heterogeneous. The findings emerge from bulk tissue analysis; single-cell resolution of the identified cell types and their cross-talk would strengthen the mechanistic insights.
Finally, no experimental validation (cell culture, xenografts, CRISPR perturbations) is included. Functional tests of whether the identified signatures drive aggression would be valuable.
What Comes Next
Natural follow-ups include prospective validation of the spatial omics signatures in independent prostate cancer cohorts, ideally integrated into clinical workflows at the time of diagnosis. Single-cell spatial omics (e.g., Visium HD or MERFISH combined with scRNA-seq) could resolve individual cell types and their specific transcriptional states within the microenvironmental niches. Functional studies, such as CRISPR screens targeting the identified chemokine pathways or metabolic dependencies, could test causation. Finally, translating these signatures into a clinically deployable test (e.g., a spatial omics panel for routine pathology) would require standardization and cost reduction, both active areas in the field.
This work exemplifies how spatial multi-omics is reshaping cancer research, moving beyond morphology-only grading toward a systems view of the tumor ecosystem. Similar approaches are already being applied to spatial transcriptomics mapping immune exclusion in tumors and other cancer types, establishing spatial omics as a core technique for understanding cancer-microenvironment interactions.
The Bottom Line
Morphologically benign glands in aggressive prostate cancers harbor metabolic and immune rewiring that predicts relapse. Spatial multi-omics can detect these hidden signals and may improve risk stratification better than morphology alone. The work opens doors to targeting the immunosuppressive and metabolically altered tumor microenvironment as a strategy to prevent relapse in high-risk patients.
Source
Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment — Krossa et al., Nature Communications, November 2025.